Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.
IPO Year: 2017
Exchange: NASDAQ
Website: immuron.com.au
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past few years has been ongoing with significant positive change. We have accelerated our commercial activities through higher level of marketing, improved channel management and strategic intent. Our scientific endeavours are bearing results with strong clinical data supporting IMC's unique hyper-immune colos
MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Steven Lydeamore as Chief Executive Officer (CEO) of the Company effective 27 June 2022. Mr. Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Mr. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This i
MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Paul Brennan as an independent Non-Executive Director of the Company with effect from today. Mr Brennan has extensive experience in the health system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the company from $30M to a high
Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has received favourable feedback from the United States Food and Drug Administration (FDA) on the pre-IND (investigational new drug) information package to su
MIAMI, Aug. 21, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteM
MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Info
Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Command (NMRC), and Walter Reed Army Institute of Research (WRAIR) Silver Spring, MD, USA. The focus of this new research agreement is to develop an enhanced formulation of Travelan potentially expanding the coverage of the product as a therapeutic measure
MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on August 22nd, 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Mr. Steven Lydeamore will give a presentation and may subsequently open the floor to questions. Please submit your questions in advance to [email protected] or ask your question
MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps. Following the presentation, attendees will have the opportunity to ask questions directly to Mr. Lydeamore during a moderated Q & A session. This webinar can be viewed live via zoom & you register for FREE via the link below. https://us06web.zoom.us
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485
Sales Highlights: Global• FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia• FY 2024 AUD$3.7 million up 223% on pcp • June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter USA• FY 2024 Record sales of AUD$1.1 million up 74% on pcp • June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior quarter Canada• FY2024 AUD$0.1 million up 6637% on pcp MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529. CEO, Steven Lydeamore said, "We are excited for our third therapeutic to be heading towards Phase 2 clinical studies, demonstrating the utility of our technology platform." The increased incidence of antibiotic resistant ‘superbugs' has amplified the use of broad-spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is disruption of
MIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteMed
Sales Highlights: Global•FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp)•June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia •FY 2024 AUD$3.7 million up 223% on pcp•June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter USA •FY 2024 Record sales of AUD$1.1 million up 74% on pcp•June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior quarter Canada•FY2024 AUD$0.1 million up 6637% on pcp MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales (unaudited) of T
-6-K
To address this need, Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent CDI. IMM-529 antibodies targeting C. diff may help to clear CDI infection and promote a quicker re-establishment of normal gut flora, providing an attractive oral preventative for recurrent CDI.
Gainers Repare Therapeutics (NASDAQ:RPTX) shares rose 34.1% to $4.4 during Wednesday's pre-market session. The company's market cap stands at $186.7 million. The company's, Q1 earnings came out yesterday. Enveric Biosciences (NASDAQ:ENVB) shares increased by 16.85% to $1.04. The company's market cap stands at $7.5 million. Clover Health Investments (NASDAQ:CLOV) stock increased by 16.21% to $0.86. The company's market cap stands at $426.3 million. As per the press release, Q1 earnings came out yesterday. Envoy Medical (NASDAQ:COCH) stock rose 13.88% to $3.28. The company's market cap stands at $64.2 million. Myriad Genetics (NASDAQ:MYGN) stock moved upwards by 13.75% to $22.5. The marke
Stephen has served as a Director since 2013 and has provided valued contributions and experienced counsel to the Company. During Stephen's tenure, Immuron launched Travelan® into the USA and Canadian markets and dual listed the Company on NASDAQ (IMRN).
Shares of Ascent Solar Technologies, Inc. (NASDAQ:ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share. Ascent Solar Technologies shares dipped 50% to $0.1374 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Marin Software Incorporated (NASDAQ:MRIN) shares jumped 152% to $0.7242 after the company announced upgrades to its integration with Microsoft Advertising. Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) gained 75% to $1.9698 after the company announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high
Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings of $1.31 per share, beating market estimates of $1.25 per share. PriceSmart’s quarterly sales came in at $1.29 billion versus expectations of $1.28 billion, according to data from Benzinga Pro. PriceSmart shares surged 4.6% to $86.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Marin Software Incorporated (NASDAQ:MRIN) shares rose 76.1% to $0.5054 in pre-market trading after the company announced upgrades to its Microsoft Corp (NASDAQ:MSFT) adver
Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract, Sales Highlights: Global • FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp • Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia • FYTD Mar 2024 AUD$2.8 million up 234% on pcp • Mar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA • FYTD Mar 2024 AUD$0.8 million up 35% on pcp • Mar 2024 Quarter AUD$0.3 million up
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. The company's market cap stands at $16.3 million. Xilio Therapeutics (NASDAQ:XLO) stock moved upwards by 223.94% to $2.07. The market value of their outstanding shares is at $56.9 million. Akanda (NASDAQ:AKAN) shares increased by 27.1% to $0.21. The company's market cap stands at $1.8 million. Kintara Therapeutics (NASDAQ:KTRA) shares rose 23.01% to $0.11. The market value of their outstanding shares is at $4.2 million. Akebia Therapeutics (NASDAQ:AKBA) stock increased by 18.34% to $2.65. The company's market cap stands at $555.0 million. INVO Bioscience (NASDAQ:INVO) stock incre
Shares of Mesoblast Limited (NASDAQ:MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Kidpik Corp. (NASDAQ:PIK) gained 238% to $9.15. Kidpik recently announced a 1-for 5 reverse stock split. TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares surged 149% to $2.6450. TRxADE HEALTH, Inc. (NASDAQ:MEDS) gained 114.6% to $17.26. TRxADE Health recently announced a special cash dividend of $8 per share. Fangdd Network Group Ltd. (NASDAQ:DUO) shares
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
EFFECT - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)
6-K - Immuron Ltd (0001660046) (Filer)